Cabozantinib Superior as Front-Line Therapy for Advanced RCC
Use of the drug is associated with significantly longer progression-free survival compared with suninitib in treatment-naïve patients.
Diagnosis & Disease Information
TKI Dose Escalation After mRCC Progression Beneficial
In a small study, researchers observed a decrease in tumor burden and extended duration of therapy.
High BMI Predicts Improved RCC Patient Survival
Paradoxical association could be related to an altered fatty acid pathway.
Kidney Cancer Risk Linked to Metalworking Fluids
Mean exposure of 18.80 mg/m3 per year was associated with a significant 11% increased risk among white men.
Active Surveillance Possible Before Treatment in mRCC
Some metastatic RCC patients may safely undergo surveillance prior to starting systematic therapy.
Metabolic Factors Linked to RCC Treatment Resistance
Research results provide potential new targets for combination therapy regimens.
Chest X-Rays May Miss Pulmonary Metastases in T1a RCC Patients
Findings in patients treated for T1a renal cell carcinoma followed with X-ray surveillance.
Cabozantinib Shows Superiority in Treating Advanced mRCC
The drug significantly improves overall and progression-free survival compared with everolimus, researchers report.
Early Tumor Shrinkage Predicts mRCC Treatment Outcomes
The optimal tumor shrinkage threshold for predicting overall and progression-free survival is 10%, researchers concluded.
AKI After RCC Surgery On the Rise
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
- Loading...
Loading...
Next post in Acute Kidney Injury
Loading... 
Loading...